Ranolazine following percutaneous coronary intervention: For whom? For what?

References

• Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl 4):iv6–iv14. doi:10.1136/hrt.2005.078790.
   PubMed Web of Science ®Google Scholar
• McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93(1):135–142.
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–575. doi:10.1016/j.jacc.2006.05.044.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al., Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–1382. DOI:10.1016/j.jacc.2003.11.045.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO, et al., Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Jama. 2004;291(3):309–316. DOI:10.1001/jama.291.3.309.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al., Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Jama. 2007;297(16):1775–1783. DOI:10.1001/jama.297.16.1775.
   PubMed Web of Science ®Google Scholar
• Weisz G, Genereux P, Iniguez A, et al., Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2016;387(10014):136–145.
   PubMed Web of Science ®Google Scholar
• Alexander KP, Weisz G, Prather K, et al., Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016;133(1):39–47. DOI:10.1161/CIRCULATIONAHA.115.019768. Epub 2015 Nov 10.
   Web of Science ®Google Scholar
• Bairey Merz CN, Handberg EM, Shufelt CL, et al., A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2015 Nov 27. pii: ehv647. [Epub ahead of print].
   Google Scholar
• Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, et al., Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 Trial. Clin Cardiol. 2015;38(8):469–475. DOI:10.1002/clc.22425.
   PubMed Web of Science ®Google Scholar
• Wittes J. On looking at subgroups. Circulation. 2009;119(7):912–915. doi:10.1161/CIRCULATIONAHA.108.836601.
   PubMed Web of Science ®Google Scholar
• Wald DS, Morris JK, Wald NJ, et al., Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115–1123. DOI:10.1056/NEJMoa1305520.
   PubMed Web of Science ®Google Scholar
• De Bruyne B, Pijls NH, Kalesan B, et al., Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001. DOI:10.1056/NEJMoa1205361.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Chaitman BR, et al., Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119(15):2032–2039. DOI:10.1161/CIRCULATIONAHA.107.763912.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Arnold SV, Spertus JA, et al., Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–2045. DOI:10.1016/j.jacc.2013.02.011.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, et al., Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647–1652. DOI:10.1161/CIRCULATIONAHA.107.724880.
   PubMed Web of Science ®Google Scholar
• Frommeyer G, Schmidt M, Clauss C, et al., Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur J Heart Fail. 2012;14(12):1322–1331. DOI:10.1093/eurjhf/hfs163.
   PubMed Web of Science ®Google Scholar
• Coppini R, Ferrantini C, Yao L, et al., Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127(5):575–584. DOI:10.1161/CIRCULATIONAHA.112.134932.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Belardinelli L, Chaitman BR, et al., Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Europace. 2015;17(1):32–37. DOI:10.1093/europace/euu217.
   PubMed Web of Science ®Google Scholar
• Mihos CG, Krishna RK, Kherada N, et al. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. Pharmacol Res. 2016;103:49–55. doi:10.1016/j.phrs.2015.10.018.
   PubMed Web of Science ®Google Scholar